The vouchers cut down the FDA review process from 12 months to one to two months, making psychedelics potentially available ...

President Trump issued an executive order to fast-track psychedelic therapies like ibogaine to treat PTSD and other mental ...

EBR Systems is closer to entering the Australian market with its WiSE cardiac resynchronisation therapy (CRT) system after ...

Ali Hashemi, Co-Founder of Metabolic, said demand reflects both patient interest in needle-free treatment options and the ...

Novartis’ Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification.

After an executive order, the FDA announced it would prioritize the study of some psychedelic drugs for therapeutic use.

Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04 ...

Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab-rzaa ...

Johnson & Johnson secured fast-track status for its autoimmune drug Imaavy, accelerating the regulatory timeline for what could become the first approved treatment for warm autoimmune hemolytic anemia ...

The Supreme Court appeared split Monday over whether to allow lawsuits against Bayer for not including a warning label about cancer risks on its Roundup weedkiller to proceed, as the company and the ...

CDSCO proposed the system in January 2026 as part of an amendment to the New Drugs and Clinical Trial Rules, 2019. The system ...

Here's what we know about daraxonrasib, a drug currently under review by the FDA.